Related Experiment Videos
[Antibacterial activities of piperacillin in several fresh clinical isolates]
K Matsuzaki1, H Koyama, K Omika
1Chemotherapy Division, Mitsubishi-Kagaku Bio-Clinical Laboratories, Tokyo, Japan.
Abstract:
We investigated activity of piperacillin (PIPC) in comparison with 8 antibacterial reference drugs against several fresh clinical strains isolated from patients with infectious diseases in the respiratory tract and after surgical interventions in 1999. The following results were obtained: 1. PIPC had its MIC90 of 0.12-6 micrograms/ml in Gram-positive bacteria (Methicillin susceptible Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus pneumoniae, Enterococcus faecalis) and showed its MIC of 1 microgram/ml or higher in 9 possible PRSP strains out of 38 isolates of S. pneumoniae but there were no possible isolates with evident resistance in other species of bacteria. 2. PIPC showed favorable antibacterial activities as its MIC90 were 2-8 micrograms/ml in Gram-negative bacteria (Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Citrobacter freundii, Pseudomonas aeruginosa, Moraxella (Branhamella) catarrhalis, Haemophilus influenzae), except for P. mirabilis in which its MIC90 was as high as 64 micrograms/ml. 11 out of 39 isolates of P. mirabilis were resistant to other drugs such as PIPC, ABPC, CTM and CZOP. 3. PIPC had its MIC90 of > 128 micrograms/ml in Bacteroides fragilis. From these results, PIPC was considered highly effective in several infections in view of maintaining its favorable antibacterial activities in several causative bacteria even today when 20 years had passed since its first application to clinical practice.
Insights
Piperacillin (PIPC) demonstrated significant activity against Gram-positive and Gram-negative bacteria, including common respiratory and post-surgical pathogens. This antibiotic maintained its effectiveness against various clinical strains, highlighting its enduring clinical value.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Antibiotic resistance is a growing concern in treating bacterial infections.
- Piperacillin (PIPC) has been a clinically used antibiotic for decades.
- Evaluating the current activity of established antibiotics against contemporary clinical isolates is crucial.
Purpose of the Study:
- To assess the in vitro activity of piperacillin (PIPC) against recent clinical bacterial isolates.
- To compare PIPC's efficacy with other reference antibacterial drugs.
- To determine PIPC's relevance in treating respiratory tract and post-surgical infections.
Main Methods:
- Collected fresh clinical bacterial strains from patients in 1999.
- Determined the Minimum Inhibitory Concentration 90 (MIC90) values for PIPC and 8 reference drugs.
- Tested activity against Gram-positive bacteria, Gram-negative bacteria, and anaerobic bacteria.
Main Results:
- PIPC exhibited potent activity against Gram-positive bacteria (MIC90: 0.12-6 µg/ml), with limited resistance in Streptococcus pneumoniae.
- Favorable activity was observed against most Gram-negative bacteria (MIC90: 2-8 µg/ml), except for Proteus mirabilis.
- PIPC showed high MIC90 (>128 µg/ml) against Bacteroides fragilis, indicating limited anaerobic activity.
Conclusions:
- Piperacillin (PIPC) remains a highly effective antibiotic against a broad spectrum of Gram-positive and Gram-negative bacteria relevant to clinical infections.
- Despite some resistance noted in specific strains like P. mirabilis and B. fragilis, PIPC's overall activity is well-maintained.
- The study underscores PIPC's continued importance in clinical practice for managing infectious diseases.